Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461397 | PMC |
| http://dx.doi.org/10.1111/1468-0009.12253 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stress and Burnout in Training; Requiem for the Surgical Dream.
J Surg Educ
June 2021
Wales PGMDE School of Surgery, Health Education and Improvement Wales, Nantgarw, United Kingdom.
Objective: Burnout among trainee doctors is common with as many as two-thirds reporting poor health. This study aimed to assess burnout in a cohort of UK core and higher general surgical trainees.
Design: The Maslach Burnout Inventory for Medical Personnel was distributed to 158 surgical trainees to evaluate emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA).
Editorial: Epratuzumab: Reveille or Requiem? Teachable Moments for Lupus and Sjögren's Syndrome Clinical Trials.
Arthritis Rheumatol
May 2018
Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles.
2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010?
Clin J Am Soc Nephrol
May 2010
Renal Department, Guy's Hospital, King's Health Partners, London, United Kingdom.
The recombinant human erythropoietins and allied proteins (epoetin alfa, attempted copies and biosimilar variants of epoetin alfa, epoetin beta, epoetin delta, epoetin zeta, epoetin theta, epoetin omega, darbepoetin alfa, and methoxy-polyethylene glycol-epoetin beta) are among the most successful and earliest examples of biotechnologically manufactured products to be used in clinical medicine. This article charts a brief history of their use in clinical medicine, mainly dealing with chronic kidney disease, paying special attention to how these agents were introduced into clinical medicine and what has happened subsequently; in 2009, there were several developments that could be regarded as a "perfect storm" in terms of the long-term use of these compounds in chronic kidney disease and oncology and, likely, elsewhere. We are now very much at a "crossroads," where mature reflection is required, because with the latest trials and meta-analyses, these therapies seem not only expensive but also very much a clinical tradeoff (increased risk of adverse effects versus a small gain in fatigue scores).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!